Deep Brain StimulationParkinsons Disease Market

Deep brain stimulation (DBS) is a neurosurgical procedure involving the placement of a medical device called a neurostimulator (sometimes referred to as a "brain pacemaker"), which sends electrical impulses, through implanted electrodes, to specific targets in the brain. DBS is used to manage some of the symptoms of Parkinson's Disease that cannot be adequately controlled with medications. It is recommended for people who have PD with motor fluctuations and tremor inadequately controlled by medication, or to those who are intolerant to medication, as long as they do not have severe neuropsychiatric problems.

Deep Brain StimulationParkinsons Disease Market contains market size and forecasts of Deep Brain Stimulation in Parkinson's Disease in Global, including the following market information:

• Global Deep Brain Stimulation in Parkinson's Disease Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Deep Brain Stimulation in Parkinson's Disease market was valued at 862.2 million in 2021 and is projected to reach US$ 1555.5 million by 2028, at a CAGR of 8.8% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Dual Channel Deep brain Stimulator Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Deep Brain Stimulation in Parkinson's Disease include Abbott, Aleva Neurotherapeutics SA, Beijing PINS Medical Co, Boston Scientific Corporation, Functional Neuromodulation Ltd, Medtronic, Neuronetics Inc., NeuroPace Inc. and Nevro Corporation. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Deep Brain Stimulation in Parkinson's Disease companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Deep Brain Stimulation in Parkinson's Disease Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Deep Brain Stimulation in Parkinson's Disease Market Segment Percentages, by Type, 2021 (%)

• Dual Channel Deep brain Stimulator
• Single Channel Deep brain Stimulator

Global Deep Brain Stimulation in Parkinson's Disease Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Deep Brain Stimulation in Parkinson's Disease Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Neurology Clinics
• Research Centers

Global Deep Brain Stimulation in Parkinson's Disease Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Deep Brain Stimulation in Parkinson's Disease Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Deep Brain Stimulation in Parkinson's Disease revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Deep Brain Stimulation in Parkinson's Disease revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Abbott
• Aleva Neurotherapeutics SA
• Beijing PINS Medical Co
• Boston Scientific Corporation
• Functional Neuromodulation Ltd
• Medtronic
• Neuronetics Inc.
• NeuroPace Inc.
• Nevro Corporation